Experience

Poseida Therapeutics, Inc.

• United States
• Biotechnology Research
• 200 - 300 Employee

• Research Scientist II

  • Apr 2022 - Present

  *CAR-T cell platform development and genotoxicity assessment *CAR-T cell platform development and genotoxicity assessment



Biosplice Therapeutics

• United States
• Biotechnology
• 1 - 100 Employee

• Scientist III

  • May 2021 - Mar 2022

  o Comprehensive immunophenotyping (in-vitro and in-vivo) and multi-omics profiling to understand role of CLK/DYRK kinase inhibition in the tumor microenvironment o Regular presentation of results at company-wide project team meetings o Supervision of 1 FTE o Comprehensive immunophenotyping (in-vitro and in-vivo) and multi-omics profiling to understand role of CLK/DYRK kinase inhibition in the tumor microenvironment o Regular presentation of results at company-wide project team meetings o Supervision of 1 FTE



La Jolla Institute for Immunology

• United States
• Research Services
• 300 - 400 Employee

• Post-doctoral Researcher

  • Oct 2020 - May 2021

  I performed Mass cytometry to decipher the heterogeneity of monocytes in patients treated with immune checkpoint therapy. Novel monocytes subsets expressing key surface markers were discovered in patients responsive to immune checkpoint therapy. I performed Mass cytometry to decipher the heterogeneity of monocytes in patients treated with immune checkpoint therapy. Novel monocytes subsets expressing key surface markers were discovered in patients responsive to immune checkpoint therapy.



Weill Cornell Medicine

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Postdoctoral Research Fellow

  • 2017 - 2019

  I lead and developed projects elucidating the transcriptome of the vasculature of different organs throughout most stages of development. We utilized single-cell RNA sequencing, next generation sequencing, histological validation, and well as mouse knockout models in vivo and in vitro to screen and discover genes that were unique and important for developmental processes. We subsequently focused on tumor cell heterogeneity using this same workflow. Through these projects I became… Show more I lead and developed projects elucidating the transcriptome of the vasculature of different organs throughout most stages of development. We utilized single-cell RNA sequencing, next generation sequencing, histological validation, and well as mouse knockout models in vivo and in vitro to screen and discover genes that were unique and important for developmental processes. We subsequently focused on tumor cell heterogeneity using this same workflow. Through these projects I became proficient and knowledgeable in:  Transcriptomics associated with high throughput sequencing and single-cell RNA sequencing  Parameter knowledge in single-cell processing pipelines: Seurat, Monocle, SCENIC  Organoid/tumor vascularization techniques  An array of modern molecular biology techniques including CRISPR, shRNA, and lentiviral gene transduction Show less I lead and developed projects elucidating the transcriptome of the vasculature of different organs throughout most stages of development. We utilized single-cell RNA sequencing, next generation sequencing, histological validation, and well as mouse knockout models in vivo and in vitro to screen and discover genes that were unique and important for developmental processes. We subsequently focused on tumor cell heterogeneity using this same workflow. Through these projects I became… Show more I lead and developed projects elucidating the transcriptome of the vasculature of different organs throughout most stages of development. We utilized single-cell RNA sequencing, next generation sequencing, histological validation, and well as mouse knockout models in vivo and in vitro to screen and discover genes that were unique and important for developmental processes. We subsequently focused on tumor cell heterogeneity using this same workflow. Through these projects I became proficient and knowledgeable in:  Transcriptomics associated with high throughput sequencing and single-cell RNA sequencing  Parameter knowledge in single-cell processing pipelines: Seurat, Monocle, SCENIC  Organoid/tumor vascularization techniques  An array of modern molecular biology techniques including CRISPR, shRNA, and lentiviral gene transduction Show less